Scarica l'app Stockscreener
2.795
9.72%
-0.301
Dopo l'orario di chiusura:
2.66
-0.135
-4.83%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.096
Aprire:
$3.04
Volume 24 ore:
126.28K
Relative Volume:
2.59
Capitalizzazione di mercato:
$8.22M
Reddito:
-
Utile/perdita netta:
$-9.64M
Rapporto P/E:
-0.4037
EPS:
-6.9236
Flusso di cassa netto:
$-10.11M
1 W Prestazione:
-26.45%
1M Prestazione:
-0.89%
6M Prestazione:
-6.83%
1 anno Prestazione:
+1.64%
Intervallo 1D:
$2.69
$3.09
Intervallo di 1 settimana:
$2.69
$3.85
Portata 52W:
$1.72
$4.10
Gt Biopharma Inc Stock (GTBP) Company Profile
Nome
Gt Biopharma Inc
Settore
Industria
Telefono
(800) 304-9888
Indirizzo
505 MONTGOMERY STREET, SAN FRANCISCO
Confronta GTBP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| 0.2846 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
0.3999 | 544.73M | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.62 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.155 | 316.76M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
SHMD
Schmid Group N V
|
2.69 | 118.42M | 0 | 0 | 0 | 0.00 |
|
DAVEW
Dave Inc
|
2.16 | 0 | 0 | 0 | 0 | 0.00 |
Gt Biopharma Inc Stock (GTBP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-02 | Iniziato | ROTH MKM | Buy |
| 2021-05-24 | Iniziato | H.C. Wainwright | Buy |
| 2021-04-13 | Iniziato | B. Riley Securities | Buy |
| 2021-03-17 | Iniziato | ROTH Capital | Buy |
Gt Biopharma Inc Borsa (GTBP) Ultime notizie
GT Biopharma (GTBP) Enhances Board with New Appointment | GTBP S - GuruFocus
GT Biopharma appoints David Mun-Gavin to board of directors By Investing.com - Investing.com South Africa
GT Biopharma appoints David Mun-Gavin to board of directors - Investing.com
GT Biopharma Appoints New Member To Its Board Of Directors - MarketScreener
GT Biopharma (GTBP) Enhances Board with New Appointment | GTBP Stock News - GuruFocus
GT Biopharma Appoints New Member to its Board of Directors - GlobeNewswire
GT Biopharma Strengthens Board Before Critical Cancer Drug Results: Banking Expert Joins NK Cell Pioneer - Stock Titan
GTBP: GT Biopharma Plans Major Stock Sale | GTBP Stock News - GuruFocus
GT Biopharma registers 120.6M shares for resale by selling stockholders - MSN
GT Biopharma Amends Share Purchase Agreement - TipRanks
GT Biopharma Reports Improved Quarterly Losses - TipRanks
GT Biopharma Expands Convertible Preferred Stock Offering - TipRanks
The Escalator: Zealand Pharma, GT Biopharma, PointClickCare and more - Medical Marketing and Media
This Natural Killer Treatment Could Help Transform How Cancer is Treated - Baystreet.ca
GT Biopharma, Inc. - MENAFN.com
GT Biopharma advances to next trial phase for cancer therapy By Investing.com - Investing.com South Africa
Ellis Martin Report: Goliath Resources Limited (CVE:GOT) Continues to Provide High Grade Gold Discoveries at Surebet in British Columbia - ABN Newswire
Ellis Martin Report: GT Biopharma Inc's (NASDAQ:GTBP) Michael Breen: Targeting Cancer Cells with a Natural Killer Based Immunotherapy - ABN Newswire
Stocks In Play - Baystreet.ca
Stocks In Play: GT Biopharma, Inc. By Baystreet.ca - Investing.com Canada
Ellis Martin Report: Blue Lagoon Resources (CNSX:BLLG) Weeks Away from Gold Production at the Dome Mountain Project - ABN Newswire
GT Biopharma advances to next trial phase for cancer therapy - Investing.com Australia
GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals - marketscreener.com
GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 - GlobeNewswire
GT Biopharma Phase 1 Trial Reveals Early Success: Cancer Drug Shows Safety and Immune Activation - Stock Titan
EXCLUSIVE: GT Biopharma Advances Relapsed Blood Cancer Therapy Trial To Cohort 2 After Promising Early Safety Results - Benzinga
GT Biopharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
GT Biopharma appoints new board member By Investing.com - Investing.com Nigeria
GT Biopharma (GTBP) Welcomes New Board Member Andrew Ritter | GTBP Stock News - GuruFocus
TSX Yet to Run out of Steam - The Globe and Mail
GT Biopharma appoints new board member - Investing.com
GT Biopharma Strengthens Board with Biotech Exit Expert Andrew Ritter: 3 Successful Company Sales - Stock Titan
GT Biopharma adds Hilary Kramer to Board of Directors By Investing.com - Investing.com South Africa
GT Biopharma (GTBP) Appoints Hilary Kramer to Board of Directors - GuruFocus
GT Biopharma adds Hilary Kramer to Board of Directors - Investing.com
$12B Portfolio Expert Hilary Kramer to Guide NK Cell Pioneer GT Biopharma's Clinical Expansion - Stock Titan
GT Biopharma (GTBP) Appoints Hilary Kramer to Board of Directors | GTBP Stock News - GuruFocus
Gt Biopharma Inc Azioni (GTBP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.68%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):